Search results
Results from the WOW.Com Content Network
[4] Menotropin preparations are designed for use in selected women where they stimulate the ovaries to mature follicles, thus making them more fertile. They are administered by typically daily injection, intramuscularly or subcutaneously, for about ten days under close supervision to adjust dose and duration of therapy.
The dosage is adjusted to each individual's response. [2] The most common side effects are abdominal or pelvic pain, bloating, as well as redness, pain or swelling at the injection site. Follitropin is possibly associated with increased risk of endometrial carcinoma.
In men: Used to treat select cases of Hypogonadotropic Hypogonadism in adult males. [25] In off-label use, some urologists prescribe hCG in low doses in combination with testosterone replacement to preserve fertility. [26] In male children: Also used to treat prepubertal cryptorchidism not due to anatomical obstruction.
ATC code G03 Sex hormones and modulators of the genital system is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.
25–50 mg 1x/6–12 weeks Prasterone enanthate a: Gynodian Depot: Oil solution: 200 mg 1x/4–6 weeks Implant: Testosterone: Testopel: Pellet: 50–100 mg 1x/3–6 months Notes: Premenopausal women produce about 230 ± 70 μg testosterone per day (6.4 ± 2.0 mg testosterone per 4 weeks), with a range of 130 to 330 μg per day (3.6–9.2 mg per ...
Trough estradiol levels and MADRS Tooltip Montgomery–Åsberg Depression Rating Scale scores with 1 mg sublingual micronized estradiol 3 to 8 times per day (3 to 8 mg/day total; mean 4.8 mg/day total) in women with postpartum depression. [8] Blood was drawn specifically in the mornings before the first dose of sublingual estradiol for the day. [8]
Clinical studies have shown that, one hour after injection, the incidence of at least one moderate or severe local skin reaction per treatment cycle was 12% in 4 patients treated with ganirelix and 25% in patients treated subcutaneously with a GnRH agonist. The local reactions generally disappear within 4 hours after administration. [4]
[202] [4] The bioavailability of MPA with oral administration is approximately 100%. [4] A single oral dose of 10 mg MPA has been found to result in peak MPA levels of 1.2 to 5.2 ng/mL within 2 hours of administration using radioimmunoassay. [202] [203] Following this, levels of MPA decreased to 0.09 to 0.35 ng/mL 12 hours post-administration.